Melanocortin Receptor Agonists
Bremelanotide
Also known as PT-141 · Vyleesi
FDA-approved for specific indicationsFDA-approved
Last reviewed: 2026-11-19
Class & structure
A 7-amino-acid chain.
How it’s thought to work
Activates melanocortin receptors, including central pathways; receptor activity does not define every clinical outcome.
Key sources
Indication-specific regulatory sources and editorial screen checked November 19, 2026. This is not an exhaustive systematic review; consult current labels.